Huey-Ling Chen, Chien-Nan Lee, Chin-Hao Chang, Ming-Wei Lai, Ming-Chieh Tsai, Shu-Chi Mu, Chun-Jen Liu, Jin-Chung Shih, Wan-Hsin Wen, Rui-Ting Hu, Chun-Pin Huang, Kuang-Chun Hu, Chie-Pein Chen, Chyi-Long Lee, Rong-Nan Chien, Kai-Chi Chang, Hong-Yuan Hsu, Chien-Chang Lee, Yen-Hsuan Ni, Mei-Hwei Chang
BACKGROUND: The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother-to-child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation. METHODS: The maternal and infant outcomes were compared in multi-centre trials of high viral load HBsAg/HBeAg+ pregnant women receiving TAF or TDF from the third trimester until 2 weeks postpartum with intensive follow-ups...
March 8, 2024: Liver International: Official Journal of the International Association for the Study of the Liver